

Online Supplement

Table S1. Baseline characteristics per prespecified subgroup (based on FeNO-level)

A. Subgroup with low level (< 25 ppb)				
	Ca-Strategy (N = 71)	FCa-Strategy (N = 63)	Difference (95% CI)	p-value
ACQ	0.98 (0.80)	0.95 (0.73)	0.04 (-0.23;0.30)	0.93
AQLQ	5.78 (0.92)	5.74 (0.93)	0.04 (-0.28;0.35)	0.80
Beclomethasone equivalent (mcg)	915 (716)	895 (619)	20 (-210;250)	0.72
B. Subgroup with intermediate level (25-50 ppb)				
	Ca-Strategy (N = 14)	FCa-Strategy (N = 13)	Difference (95% CI)	p-value
ACQ	0.68 (0.69)	0.87 (0.28)	-0.19 (-0.61;0.24)	0.14
AQLQ	6.26 (0.72)	5.85 (0.98)	0.41 (-0.27;1.08)	0.16
Beclomethasone equivalent (mcg)	621 (683)	738 (762)	-117 (-690;456)	0.56
C. Subgroup with high level (50 ppb)				
	Ca-Strategy (N = 9)	FCa-Strategy (N = 9)	Difference (95% CI)	p-value
ACQ	0.74 (0.46)	1.01 (0.83)	-0.27 (-0.94;0.40)	0.48
AQLQ	5.99 (0.71)	6.17 (0.88)	-0.17 (-0.97;0.63)	0.35
Beclomethasone equivalent (mcg)	722 (570)	444 (407)	228 (-217;772)	0.26
D. Combined subgroups with intermediate/high level (>25 ppb)				
	Ca-Strategy (N = 23)	FCa-Strategy (N = 22)	Difference (95% CI)	p-value
ACQ	0.70 (0.60)	0.92 (0.56)	-0.22 (-0.57;0.13)	0.16
AQLQ	6.16 (0.71)	5.98 (0.93)	0.18 (-0.32;0.67)	0.68
Beclomethasone equivalent (mcg)	661 (629)	618 (646)	43 (-341;426)	0.87

Ca = Controlled asthma

FCa = Feno-driven controlled asthma

ACQ = Asthma Control Questionnaire

AQLQ = Asthma Quality of Life Questionnaire

CI = confidence interval

† As a post-hoc analysis we pooled the intermediate and high FeNO-subgroups (> 25 ppb) because of the low number of patients in these FeNO-subgroups separately.